| CEO Name | Michael M. Morrissey |
| Nationality | United States |
| Net Worth Estimation | $60 million |
Michael M. Morrissey's estimated net worth of around $60 million is primarily due to his executive compensation, stock holdings, and stock options accrued as CEO and President of Exelixis, Inc. His long tenure since 2010, significant equity grants, and performance-based bonuses tied to Exelixis' commercial successes have substantially increased his wealth.
Michael M. Morrissey, CEO of Exelixis in the biotechnology sector, has an estimated net worth of $60,000,000. His net worth is 78.57% of the maximum ($80,000,000) and six times the minimum ($10,000,000) estimated CEO net worth in this business category.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Michael M. Morrissey Performance in Exelixis
Michael M. Morrissey, CEO of Exelixis, demonstrates strategic leadership by driving robust decision-making focused on innovation and sustainable growth in oncology treatments. His performance is marked by successful pipeline advancements and strengthened market positioning, enhancing shareholder value. Morrissey's impact includes expanding Exelixis' global footprint and accelerating drug approvals, solidifying the company's status as a leader in targeted cancer therapies.
Latest News
Exelixis CEO Michael Morrissey Highlights Strong Q3 2025 Growth and Strategic Focus
Exelixis reported a 10.8% revenue increase in Q3 2025, driven by successes in drug trials such as STELLAR-303 and CABINET, with CEO Michael Morrissey emphasizing commitment to oncology innovation and disciplined R&D investment, backed by a $750 million share repurchase plan. The company is optimizing operations, including closing a Pennsylvania office, as it advances key cancer therapies like cabozantinib and zanzalintinib.
Source: http://intellectia.ai/earnings/exelixis-earnings-drug-trial-success